Home
overview
Medical imaging has become a critical part of the clinical trial process and is essential in terms of study outcomes. Imaging is also beginning to have more of an influence at the discovery and preclinical stages and the application of new techniques holds some exciting potential, particularly in the treatment of cancer.

SMi’s Imaging in Oncology Conference will provide up to date, practical information on the latest developments in this rapidly evolving field and how it can be applied to cancer drug development, bringing together leading researchers involved in all aspects of oncological research and those with a specific interest in image formation, analysis and interpretation of imaging data.

The event aims to assess the latest development in imaging technologies with a specific focus on how they can be applied for maximum effect to the drug development process both at the preclinical and clinical stages. The event will outline the latest regulatory requirements and provide a comprehensive overview of how to submit material to the regulatory authorities. It will look at the advances in techniques including perfusion imaging and will evaluate technological advances in internet imaging services and software for image evaluation.

A unique opportunity to learn from leading industry experts including:
· Dr Jonathan Allis, Vice President, Technology, Amersham Health
· Dr John Waterton, Director, Imaging, Discovery Enabling Science Technology & Information, AstraZeneca
· Dr Philip Murphy, Clinical Project Manager, Clinical Technology, Pfizer
· Dr Padmaja Yalamanchili, Senior Research Investigator, Bristol Myers Squibb Medical Imaging
· Dr Ellen Fiegal, Acting Director, Division of Cancer Treatment & Diagnosis, National Cancer Institute
· Dr Anwar Padhani, Consultant Radiologist & Lead, Magnetic Resonance Imaging, Paul Strickland Scanner Centre, Mount Vernon Hospital

Benefits of Attending:
· IMAGING IN ONCOLOGY: Assess the influence of imaging in oncology drug discovery and development
· CLINICAL TRIALS: Understand the practical application of imaging techniques through the clinical trials process
· TECHNOLOGY PLATFORMS: Evaluate current imaging methods and technologies, including MRI, Ultrasound, PET and CT
· TECHNICAL ADVANCES: Assess the latest developments with a specific focus on how they can be applied
· KEY INDUSTRY PERSONNEL: Meet the leaders in the field and learn from their experiences

"An important opportunity to learn how to apply imaging for improved decision-making and for seeking accelerated approvals in Oncology."
Dr Craig Lipset, Senior Director, Perceptive Informatics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Donald Rosen

Dr Donald Rosen, Chief Technology Officer & Co-Founder, RadPharm

9:10 KEYNOTE ADDRESS

Dr Jonathan Allis

Dr Jonathan Allis, Vice President, Technology, Amersham Health

  • Cancer imaging - improving the quality of detection and more precise therapy and surgery
  • Supporting various tumour - destroying approaches such as chemicals, radiation and gene therapy
  • Understanding the molecular make up of cancer drives the direction of current imaging research
  • New technologies and new opportunities
  • The application of recent imaging technological advances
  • The importance of quantitative imaging in drug development and monitoring therapy
  • Looking to the future - the development of biosensors
  • 9:40 NATIONAL CANCER INSTITUTE AND IMAGING

    Dr Ellen Feigal

    Dr Ellen Feigal, Acting Director, Division of Cancer Treatment & Diagnosis, National Cancer Institute

  • NCI’s role in catalyzing and fostering cancer imaging
  • Specific initiatives and illustrative examples in probe development, biomarkers and clinical trials
  • Interactions with FDA and CMS to foster technology development and the lessons learned to date
  • Financial investment in imaging
  • Future directions
  • 10:20 WEAVING IMAGING INTO THE DEVELOPMENT OF NEW DRUGS FOR ONCOLOGY

    Dr P David Mozley

    Dr P David Mozley, Medical Advisor, Eli Lilly

  • Imaging in early development
  • Proving that drugs can penetrate the tissue of interest, hit the intended target and quantify the fraction of dose hitting non-intended tissues as a consequence
  • Imaging as an aid to enhancing human research subject safety, the quality of data and the speed of development
  • 11:00 Morning Coffee

    11:20 IMAGING MOLECULAR TARGETS: PRECLINICAL STUDIES

    Dr Padmaja Yalamanchili

    Dr Padmaja Yalamanchili, Senior Research Investigator, Bristol Myers Squibb Medical Imaging

  • Selecting relevant targets in cancer tissues
  • Identifying small molecule inhibitors to biological targets
  • Developing radiolabeled small molecule inhibitors
  • Imaging tumours with radiolabeled small molecules
  • 12:00 FROM PRECLINICAL TO CLINICAL DEVELOPMENT

    Dr John Waterton

    Dr John Waterton, Director, Imaging, Discovery Enabling Science Technology & Information, AstraZeneca

  • Translational science to deliver imaging biomarkers for clear go-no go decisions in Phase I/II oncology development
  • Devising an integrated programme of clinical and preclinical work
  • What do “validation” and “reproducibility” really mean?
  • Finding a signal: target, pathway, cell, physiology, morphology…?
  • MRI, PET or other imaging technologies?
  • Future implications for the drug development process
  • 12:40 Networking Lunch

    14:00 INCREASING SPEED AND PRODUCTIVITY OF PRECLINICAL AND CLINICAL DEVELOPMENT THROUGH THE USE OF AUTOMATED QUANTITIVE IMAGE ANALYSIS

    J Mikael Totterman

    J Mikael Totterman, Chief Operating Officer, Virtual Scopics

  • Improving quality of imaging protocols and data acquisition used in clinical development
  • Automated quantitative image analysis in oncology: structural and perfusion imaging
  • Lowering cost and increasing the speed of early development for early go/no go decision making
  • Improving precision of RECIST and WHO criteria through automation
  • Impact on cost and time of drug development achieved through increased quality of imaging and application of automated quantitative image analysis
  • 14:40 MEDICAL IMAGING INFORMATICS

    Dr Ted Gastineau

    Dr Ted Gastineau, Chief Executive Officer, Beacon Bioscience

  • Comprehensive design from preclinical to approval
  • Standardized imaging protocols
  • Management and compliance for multi-center trials
  • Image analysis: match the questions with the tools
  • Image management platforms and information integration
  • Long and short term strategies
  • 15:20 Afternoon Tea

    15:40 THE ROLE OF MRS AND MRI IN VIVO AS TOOLS IN TRANSLATIONAL MEDICINE TO AID DRUG DEVELOPMENT

    Dr Paul McSheehy

    Dr Paul McSheehy, Lab Head & International Project Team Representative for EPO906, Novartis

  • MRS (1H, 31P, 19F)
  • Pharmacokinetics
  • DCE-MRI
  • DCE-MRI
  • Preclinical
  • Clinical
  • 16:20 MULTI-FUNCTIONAL NMR IN ANTI-CANCER RESEARCH

    Dr Philip Murphy

    Dr Philip Murphy, Clinical Project Manager, Clinical Technology, Pfizer

  • Exploiting intrinsic tissue contrast to study tumours
  • Advances in paramagnetic contrast agents
  • Clinical spectroscopy for monitoring treatment response
  • High-field clinical systems: 3T and beyond
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr John Waterton

    Dr John Waterton, Director, Imaging, Discovery Enabling Science Technology & Information, AstraZeneca

    9:10 EMERGING TECHNOLOGIES

    Dr Helen Young

    Dr Helen Young, Imaging Specialist (PET), AstraZeneca

  • The current status of PET imaging
  • The application of this technology to oncology clinical trials
  • The ability to understand the success rate of cancer therapy at a very early stage
  • Bottlenecks in PET imaging
  • PET vs CT or MRI - advantages, shortcomings applications and cost
  • Future prospects of PET technology
  • 9:40 COMPUTED TOMOGRAPHY

    Prof Ken Miles

    Prof Ken Miles, Professor, Imaging, Brighton & Sussex Medical School

  • Combined morphological end-points (eg RECIST) with functional imaging in a single widely-available examination
  • Technical validation and reproducibility of functional CT
  • Simplifying functional CT for multi-centre protocols
  • Advantages of multi-detector CT
  • The potential for CT to identify patient groups enriched for response
  • Functional CT/PET
  • 10:20 TARGETING TUMOUR BLOOD VESSELS

    Dr Anwar Padhani

    Dr Anwar Padhani, Consultant Radiologist & Lead, Magnetic Resonance Imaging & Imaging Research, Paul Strickland Scanner Centre, Mount Vernon Hospital

  • The use of serial dynamic resonance imaging (MRI) to ascertain the effects of anti-angiogenics and anti-endothelial on tumour blood flow
  • MRI kinetic parameters and what they mean
  • Considerations for multi-centre studies
  • Results of MRI: do blood flow measurements predict efficacy?
  • Impact of this technique during the clinical trials process
  • 11:00 Morning Coffee

    11:20 PANEL DISCUSSION

    Prof Ken Miles

    Prof Ken Miles, Professor, Imaging, Brighton & Sussex Medical School

    Professor Fiona Gilbert

    Professor Fiona Gilbert, Professor, Radiology, University of Aberdeen

    Dr Anwar Padhani

    Dr Anwar Padhani, Consultant Radiologist & Lead, Magnetic Resonance Imaging & Imaging Research, Paul Strickland Scanner Centre, Mount Vernon Hospital

    Dr John Waterton

    Dr John Waterton, Director, Imaging, Discovery Enabling Science Technology & Information, AstraZeneca

    12:00 MANAGING THE IMAGING COMPONENT OF PHASE III ONCOLOGY STUDIES

    Dr Klaus Noever

    Dr Klaus Noever, Director, Business Development & Clinical Affairs, Europe, Bio-Imaging Technologies

  • Response assessment
  • Pitfalls in multi-centre studies
  • Regulatory requirements
  • Review designs
  • Process management
  • 12:40 Networking Lunch

    14:00 RECIST IN ONCOLOGY IMAGING

    Dr Oliver Bohnsack

    Dr Oliver Bohnsack, Associate Medical Director, Perceptive Informatics

  • Why RECIST?
  • RECIST or WHO, RECIST and WHO?
  • Shortcomings of RECIST
  • Modification and adaptation of RECIST for the design of your trial
  • 14:40 EFFECTIVELY IMPLEMENTING RECIST CRITERIA

    Dr Robert Ford

    Dr Robert Ford, Chief Medical Officer & Co-Founder, RadPharm

  • Learn the practical methods of applying RECIST and standardising imaging processes in a clinical trial situation
  • Choose the best technique to measure the targeted tumor
  • Determine the best study-wide interval to use between measurements for time to tumor progression
  • Standardise the process of tumor measurement and analysis
  • Predict and learn how to overcome the complexities
  • 15:20 Afternoon Tea

    15:40 INDEPENDENT ASSESSMENT OF TUMOR RESPONSE IN NON-HODGKIN LYMPHOMAS

    Dr Yves Miaux

    Dr Yves Miaux , Vice President, Radiology Services, Synarc

  • Definition of ‘normal’ sized lymph nodes and consequences on response rates and time to progression
  • Residual masses
  • Role of image charter
  • Role of imaging to detect side effects of treatment
  • Need for an oncologist review
  • 16:20 DATA MANAGEMENT TECHNIQUES

    Gretchen Leigh-Rhodes

    Gretchen Leigh-Rhodes, Senior Manager, Clinical Data Programs, Millennium

  • Current data management practices
  • Optimal data management platforms
  • Data management strategies
  • Establishing a credible interpretation
  • Trouble shooting
  • Case studies
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Phase III Oncology Studies For Submission To The FDA: Design Of The Imaging Component
    Workshop

    Phase III Oncology Studies For Submission To The FDA: Design Of The Imaging Component

    The Hatton, at etc. venues
    16th March 2004
    London, United Kingdom

    Incorporating independent endpoint review panels in oncology trials
    Workshop

    Incorporating independent endpoint review panels in oncology trials

    The Hatton, at etc. venues
    19th March 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.